FindTrial
Sign In

Comparison of postoperative nausea and vomiting accoring to manual and target controlled infusion of remifentanil in gynecological patients undergoing pelviscopic surgery - Randomized controlled trial -

Comparison of postoperative nausea and vomiting accoring to manual and target controlled infusion of remifentanil in gynecological patients undergoing pelviscopic surgery - Randomized controlled trial -

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0007703
Enrollment
90
Registered
2022-09-16
Start date
2022-07-18
Completion date
Unknown
Last updated
2023-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Others : The study was conducted by dividing the continuous infusion methods of remifentanil during surgery into two types: manual infusion (manual injection by determining the infusion rate per hour)

Sponsors

BCWORLD PHARM
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Patients scheduled for elective gynecological surgery using pelviscopy under general anesthesia

Exclusion criteria

Exclusion criteria: (1) 18 years old or younger, 70 years old or older (2) Pregnant women (3) Allergic to remifentanil or use is contraindicated (4) Administration of antiemetics or steroids within 24 hours before surgery (5) Obesity with a body mass index of 35 kg/m^2 or more (6) ASA classification III or higher

Design outcomes

Primary

MeasureTime frame
incidence of post operative nausea and vomiting—

Secondary

MeasureTime frame
post operative pain (NRS)—

Countries

Korea, Republic of

Contacts

Public ContactSangho Lee

Kyung Hee University Hospital

silzzang15@naver.com+82-2-958-8589

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026